Are you If not, could you forward this site to this person? |
|
 |
infomore |
I have done this site especially for Joan Gillings |
|
|
Joan is wife of Dennis Gillings chairman and chief executive officer of Quintiles Transnational Corp
 |
 |
 |
Sorry for my poor english translation.
Quintiles Transnational form a new partnership team composed of current investors Gillings, TPG and Temasek as well as newcomers Bain Capital and 3i (press release)
Quintiles Transnational Corp.., 21/12/2007: RESEARCH TRIANGLE PARK, NC, Dec. 22 / PRNewswire / - Quintiles Transnational Corp.. announced today the creation of a new investor partnership to support the continued growth of the company under the leadership of current Chairman and CEO Dennis Gillings, CBE, and the management team. Gillings and global private investment firms Bain Capital and TPG Capital are the largest investors in the partnership, with 3i also becoming a major investor. Temasek Holdings remains an investor in Quintiles ..
---
Bradley Pharmaceuticals to Acquire Bioglan Pharmaceuticals Quintiles Transnational.
RESEARCH TRIANGLE PARK, NC, June 9 / PRNewswire / - Quintiles Transnational Corp.. announced today the signing of an agreement to sell its company specializing in dermatology products, Bioglan Pharmaceuticals, the company Bradley Pharmaceuticals, Inc.. (NYSE: BDY) headquartered in New Jersey. The transaction is valued at approximately $ 183 million in cash, plus direct costs associated with the transfer of stock.
Quintiles Transnational acquired certain assets relating to Bioglan in March 2002 as part of its strategy to invest in products or pharmaceutical companies who need additional resources to achieve their full market potential.
<<Depuis L'acquisition Quintiles and training Bioglan there are more than two ans, the company and its products have performed very well résultats, meeting and exceeding even our attentes> said Dennis Gillings, Quintiles CEO Transnational.
"The success of this investment is further evidence that Quintiles has a thorough knowledge of scientific and commercial aspects of the pharmaceutical market. Quintiles will continue to use its PharmaBio Development group to look for opportunistic investments in products and companies whose success is by providing additional resources. "
Quintiles intends to use the proceeds to fund debt and fund initiatives growing.
Bradley Pharmaceuticals is a specialty pharmaceutical company marketing prescription sold, corresponding to niche market targeting a very specific audience of doctors in the United States and in 38 countries.The dermatological products are provided by its subsidiary, Doak Dermatologic.
Under the agreement signed yesterday, Bradley will acquire Bioglan's interests in dermatological products sold in the United States. These include Solaraze (R) Gel (diclofenac disodium), belonging to a new class of highly sought after topical treatment of actinic keratosis, a precancerous skin lesion, the ADOX (R) (doxycycline), produces prescription and indicated for the oral treatment of severe forms of acne; Zonalon (TM) (doxepin hydrochloride), topical treatment of pruritus and Tx Systems (R) line of advanced topical treatments used for in-office procedures.
Bioglan Pharmaceuticals employs 91 people in the United States, 61 are commercial, DG is installed at company headquarters in Malvern, Pennsylvania. Bioglan was part of PharmaBio Development, the strategic investment group of Quintiles.
This agreement should satisfy the contractual conditions of use and regulatory requirements. His signing is scheduled for the third quarter.
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical companies, biotechnology and healthcare. Quintiles headquarters is near Research Triangle Park, North Carolina. The company has offices in 50 countries and has positioned itself as the world's leading pharmaceutical services organization. For more information about the company, visit its Web site at http://www.quintiles.com.
Certain statements in this release are "forward-looking", subject to risks and uncertainties that may cause material differences with the actual results, including without limitation, the inability of parties to meet all conditions for the signing of the agreement, the possibility of delays in obtaining regulatory approvals or consents or non-issuance of such authorizations, the possibility that the transaction is delayed or does not in any way to his conclusion and the future availability of investment opportunities. Other factors that could affect actual results are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including its annual report on Form 10-K, its Quarterly Report on Form 10-Q and recent reports recorded on Form 8-K.
---
-> Created for Joan Gillings
The trial (therapeutic) transformed by WebMD / Healtheon
Quintiles, the world leader in therapeutic trials, says its information systems to start-up star of the American Medical Internet.
February 3, Healtheon / WebMD acquired the electronics business, Quintiles, Envoy, $ 2.5 billion. This pooling of skills and assets disrupt electronic medicine.
This merger announced a radical transformation of clinical trials, aimed at full tilt on the web. For Healtheon / WebMD, this transaction is in the phase of accelerated concentration that turns to bulimia.
"An historic agreement." Dennis Gillings, chairman of Quintiles Transnational corp. has much to be happy with the agreement it recently signed with Healtheon / WebMD will enable it to offer one of the most extensive offerings of Internet transaction market and the largest in the field of health.
Under the terms of the agreement, Quintiles will receive 35 million shares of Healtheon / Web MD and 400 million dollars, about $ 2.5 billion. [For details of the agreement, read the press release of Quintiles or WebMD]
The alliance announced the development and commercialization of products and services to improve the quality and speed in drug development, retail and information on internet marketing (DTC Direct to Consumers).
Since its creation, Healtheon / WebMD relies on the conversion of all transactions in the medical world to the internet. According to the company, this development will reduce the cost of the healthcare industry, which generates $ 280 billion annually in administrative and unnecessary clinical. Healtheon / WebMD intends to leave only crumbs of the market to competitors
---
Quintiles makes a new partnership announced earlier investors, co-led by founder and CEO Dennis Gillings, Bain Capital, TPG and 3i
Quintiles Transnational Corp.. announced today the completion of its new partnership announced earlier investors to support the continued growth of the company under the leadership of founder and current CEO Dennis Gillings, CBE, and the management team. Gillings and global private equity firm Bain Capital and TPG private capital have become major investors in Quintiles, while 3i also becoming a major investor. Temasek Holdings remains investor in Quintiles. Under the transaction, One Equity Partners, the private equity arm of JPMorgan Chase (NYSE: JPM), has sold its stake in the new investor partnership. The terms of the transaction were not disclosed. The Company has not incurred any new debt after the transaction.
About Quintiles Transnational
Quintiles Transnational Corp.. is the source of the next generation of healthcare by providing pharmaceutical, biotechnology and health care a wide range of professional services in drug development, financial partnering and commercialization. With approximately 20,000 employees and offices in over 50 countries, the company is dedicated to providing customer-focused solutions, which are considered the best in the industry. For more information, visit the company web site on http://www.qtrn.com.
About Bain Capital
Bain Capital (http://www.baincapital.com) is a global private investment firm that manages several pools of capital including private equity, venture capital, capital assets and opened debt leveraged, with more than 65 billion in assets under management. Since its inception in 1984, Bain Capital has made private equity investments and acquisitions in over 250 companies worldwide. It has a team of almost 300 professionals dedicated to investing in and supporting its portfolio companies. Bain Capital is an expert in investment in health care, having invested in over 50 companies including HCA, Warner Chilcott, CRC Health Group, Stericycle, M | C Communications, Wesley Jessen, and Physio Control. Bain Capital, headquartered in Boston with offices in New York, London, Hong Kong, Shanghai, Tokyo and Munich.
-> Created for Joan Gillings
About TPG Capital
TPG Capital is the global buyout group of TPG, a private investment fund founded in 1992 that manages more than $ 35 billion in assets and offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG Capital has extensive experience in public investment and private international, made in connection with acquisitions by borrowing, recapitalizations, spinouts, joint ventures and restructurings. Visit http://www.tpg.com.
About 3i
Founded in 1945, 3i is a leading international private equity and venture capital with assets of $ 16 billion. 3i invests across Europe, North America and Asia. Our competitive advantage is the result of our international network of over 250 investment professionals in 14 countries, our unparalleled industry knowledge and our extensive portfolio of approximately 750 companies. These elements are the basis of the value we deliver to our portfolio and our shareholders. Visit http://www.3i.com.
About Temasek Holdings
Established in 1974, Temasek Holdings is an Asia investment firm headquartered in Singapore. Temasek has 300 employees in several countries. Supported by affiliates and offices around Asia, it manages a diversified portfolio of $ 164 billion (108 billion), mainly focused on Asia. Temasek owns shares, and invests in various sectors such as banking and financial services, real estate, transportation & logistics, infrastructure, telecommunications & media, bioscience & healthcare, education, consumer & lifestyle, engineering & technology and energy & resources.
----
-> Site for Joan Gillings
- New association of investors co-led by founder and CEO Dennis Gillings, Quintiles, and that Bain Capital and TPG
Quintiles Transnational Corp.. announced today the creation of a new investor partnership to support the continued growth of the company under the leadership of current Chairman and CEO Dennis Gillings, CBE, and the management team. Gillings and global private investment firms Bain Capital and TPG Capital are the largest investors in the partnership, with 3i also becoming a major investor. Temasek Holdings remains an investor in Quintiles.
Under the transaction, One Equity Partners (OEP), the private equity arm of JPMorgan Chase (NYSE: JPM), will sell its stake in the new investor partnership. OEP and Gillings led the original acquisition of Quintiles along with TPG Capital in September 2003. The terms of the transaction, expected to be completed in January 2008, were not disclosed and the company announced that it will not incur any new debt as a result of the agreement.
"Our new investor partnership strengthens significantly the mark of Quintiles and its growth strategy", said Mr. Gillings, "and is the result of our performance record. We are excited to move forward with our financial partners Bain Capital, TPG, 3i and Temasek. The strength of our capital structure and partnership with these leading global investors underscore our unsurpassed ability to provide innovative solutions to the pharmaceutical and biotechnology industries. I would also like to thank One Equity Partners for their contributions the past four years. >>
Jonathan Coslet, partner at TPG, said: "We are very pleased to continue our partnership with Quintiles in the next phase of its growth, which is to help pharmaceutical and biotechnology companies to transform their business models. Dennis and his team have done a remarkable job to make Quintiles the leader in global strategic partnership, marketing and drug development. >>
-> Created for Joan Gillings
John Connaughton, managing director at Bain Capital, said: "We are very pleased to participate in funding the next phase of development for Quintiles, a market leader is well positioned to continue its success in the industries and regions of the world with growth rates the highest. We believe that Quintiles will continue to play a vital role in the provision of advances and innovations in health care to patients in need. We were very impressed by management, and we look forward to supporting its efforts to increase the international leadership of the company. >>
Robin Marshall, partner at 3i, said: "3i is delighted to partner with Quintiles in the next stage of its development. Quintiles is a world-class enterprise that will continue to have a huge impact on the health care industry. 3i will enhance its global network of health care to enable Quintiles to continue its growth. >>
About Quintiles Transnational
Quintiles Transnational Corp.. is the source of the next generation of healthcare by providing pharmaceutical, biotechnology and health care a wide range of professional services in drug development, financial partnering and commercialization. With approximately 20,000 employees and offices in over 50 countries, the company is dedicated to providing solutions focused on customer solutions considered the gold standard of the industry. For more information, please visit the company web www.qtrn.com.
About Bain Capital
Bain Capital (www.baincapital.com) is a global private investment firm that manages several pools of capital including equity, venture capital, public funds and assets borrowed, with over 65 billion USD in assets under management. Since its inception in 1984, Bain Capital has made private equity investments and acquisitions in over 250 companies worldwide. It has a team of almost 200 professionals dedicated to investing in and supporting its portfolio companies. Bain Capital is an expert in investment in health care, having invested in over 50 companies including HCA, Warner Chilcott, CRC Health Group, Stericycle, M | C Communications, Wesley Jessen, and Physio Control. Bain Capital, headquartered in Boston with offices in New York, London, Hong Kong, Shanghai, Tokyo and Munich.
-> Site for Joan Gillings
About TPG Capital
TPG Capital is the global buyout group of TPG, a private investment fund founded in 1992 that manages more than $ 35 billion in assets and offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG Capital has extensive experience in public investment and private international, made in connection with acquisitions by borrowing, recapitalizations, spinouts, joint ventures and restructurings. Please visit www.tpg.com.
About 3i
Founded in 1945, 3i is an international leader in equity and venture capital, with assets worth 16 billion USD. 3i invests across Europe, North America and Asia. Our competitive advantage is the result of our international network of over 250 investment professionals in 14 countries, our unparalleled knowledge of the industry and our extensive portfolio of approximately 750 companies. These elements are the basis of the value we deliver to our portfolio and our shareholders. Please consult the www.3i.com.
About Temasek Holdings
Established in 1974, Temasek Holdings is an Asia investment firm headquartered in Singapore. Temasek has 300 employees in several countries. Supported by affiliates and offices around Asia, it manages a diversified portfolio of $ 164 billion (108 billion), mainly focused on Asia. Temasek owns shares, and invests in various sectors such as banking and financial services, real estate, transportation & logistics, infrastructure, telecommunications & media, bioscience & healthcare, education, consumer & lifestyle, engineering & technology and energy & resources.
---
-> Site for Joan Gillings
Quintiles Appoints Pamela Kirby as Chief Executive Officer, Dennis Gillings is chairman of the board in the new organization started
RESEARCH TRIANGLE PARK, NC, March 13 / PRNewswire / - Quintiles
Transnational Corp.. (QTRN Nasdaq) announced today the implementation
a key stage of its succession plan in the long term by appointing Pamela J. Kirby
as Chief Executive Officer, at the same time consolidating the team
Company's management. Dennis Gillings, who founded the Company in 1982
remain within the company as chairman. Ms. Kirby
assume his new duties on April 2 and will report to Gillings.
-> Site for Joan Gillings
Ms. Kirby will be in charge of daily management activities
Quintiles globally, particularly in the distribution of
services and interaction with customers, investors and
employees. All officers who are currently Gillings
will now report to Ms. Kirby. Gillings will retain the position of
Chairman and will continue to serve on the steering committee
General Quintiles and oversee growth strategies and
technology strategies of the Company. There will also remain chairman of
Board of Directors.
Ms. Kirby, aged 47 years, most recently headed the department of
global strategic marketing and business development of
the pharmaceutical division of F. Hoffmann-La Roche Ltd.. in Basel, Switzerland, where
She reported to the CEO of the company. In this role, Ms. Kirby
was responsible for global marketing of all products issued
order of the society. In addition, she established and directed the Life
Cycle Organization, a cross-functional team who watched the
development of new products related inter alia by their
approval of their launch and renewal of their patent.
Before that, Ms. Kirby has spent 17 years with Astra AB and then
serve as business manager for global
British Biotech plc. During her tenure at Astra, she held various
positions, the latest being that of Vice-President of the company for
strategy development, marketing and business
including licensing. Ms. Kirby also played the role of Director
General Astra's subsidiaries in the United Kingdom and Ireland. She has held
place several times in different boards
the pharmaceutical industry. Ms. Kirby holds a Ph.D. in
Clinical Pharmacology and has an undergraduate degree in pharmacology
University of London.
"We are delighted to welcome Ms. Kirby when we made
numerous adjustments in terms of operations that we believe,
yield results this year, "said Gillings." His qualities
leader and his experience of multinational research and development
marketing will showcase Quintiles to cross the
next stage of its evolution as a business partner
Pharmaceutical and biotechnology companies. On a personal level, our relations
work are excellent. We have established a balance with respect to
decision making. The ability of Ms. Kirby to know the reason
people and approach, which goes straight to the 'allowed him to forge a
first class reputation.
"It was successful despite the turmoil in the industry
allowing pharmaceutical companies billions of dollars
increase their profits and profitability while meeting
the obligation to be accountable to investors. With his extensive
marketing experience, Ms. Kirby will orchestrate the efforts of our
strong management team to present innovative solutions to our
customers and succeed in the marketplace. "
Virginia Weldon, a member of the Board of Quintiles Transnational said
"Quintiles is lucky to have convinced Pam Kirby to join
his organization as CEO. This is a person
Outstanding in every sense of the word and it brings exactly the type
expertise that will enable Quintiles to continue its growth and
achieve its financial goals. "
Ms. Kirby said: "The strategy is attractive and well Quintiles
developed and my knowledge of the pharmaceutical world and my experience as
Quintiles of client mean that I understand the needs of
industry. I look forward to further consolidate the management model
Quintiles to serve this dynamic market in which we work. "
To introduce Ms. Kirby, Quintiles Transnational will hold a
conference call and conduct a live broadcast on the Web at 10
00 pm EST Wednesday, March 14. Those who are interested (s) may
access the Webcast at
http://www.quintiles.com/investors/broadcast_center. (In addition, a replay
on the Web will be available at the same address approximately two hours after the end
of the conference call. The replay will be available until
Friday, March 23.)
-> Site for Joan Gillings
Quintiles Transnational is the world's leading supplier
information technology and services to accelerate marketing
new drugs to patients and improve healthcare.
Quintiles is headquartered near Research Triangle Park,
North Carolina relies on a global workforce of 18,000
employees in 39 countries. Quintiles Transnational is registered
S & P 500 and Fortune 1000. For more information
Corporation, visit its Web site at www.quintiles.com.
This release contains "forward-looking statements" about Quintiles.
These statements are subject to certain risks and uncertainties that
may cause material differences with the eventual results,
including: the ability to complete the development and commercialization
new products, costs and timing of introduction of new
products on the market, compared with income they could generate
and market acceptance. Other factors that may affect the
actual results are discussed in Quintiles' recent filings by
with the Securities and Exchange Commission, including its statements
Registration on Form S-3 and S-4, its annual report on Form
10-K, its Reports on Form 8-K and its other periodic reports, including
the quarterly reports on Form 10-Q.
-> Created for Joan Gillings